HA TECH is developing a range of testing kits and reagents for both laboratory and point of care testing, including for ‘COVID-19’. The company has launched a multi-gene target SARS-CoV-2 RT-PCR kit that is one of the fastest available globally. The company is also developing a range of other diagnostic kits concurrently such as a multiplex kit for testing SARS-CoV-2, Influenza and other respiratory viruses and a kit for differentiating Dengue, Chikungunya and Zika virus. Development has also begun for a rapid SARS-CoV-2 point of care test and an environmental SARS-CoV-2 test kit.
HA TECH is collaborating with a world leading research organization to develop biotherapeutic drugs. The company is also developing a number of API products internally and via commercial partnership. The company is concentrating on the development of a key product range in Sydney and full-scale manufacturing in South East Asia, initially in Bangladesh.
Polymer hydrogel/microgels based products and applications are one of the key competencies of HA TECH. The company is developing devices and technologies for specific medical applications.